M2 EQUITYBITES-September 22, 2015-Atossa Genetics to launch Phase II clinical trial of Fulvestrant for the treatment of DCIS with its patented intraductal
The final histopathology showed intraductal
papilloma 13 (36%), duct ectasia 18(50%), DCIS 1 (2.7%), fibrocystic disease 3(8.3%) and LCIS 1(2.7%).
Only in 1997 the term intraductal
papillary mucinous neoplasms (IPMN) was introduced by the WHO (Word Health Organization) [1,10].
Papilloma Market" Report of Market Research Future (MRFR)'s Explores Scope of the Study as Research Objective, Assumptions and Limitations in-depth.
With the application of advanced imaging techniques, pancreatic intraductal
lesions are being detected at an enormously increasing rate, but the majority of these lesions belong to pancreatic IPMN.
This study aimed to report the clinical presentation of a female patient with SCAP of the nipple recurring with intraductal
papilloma (IP), whose microscopic features are similar and create a dilemma for the pathologists in accordance with the literature.
(1,5,43) Cribriform lesions that have features borderline between IDC-P and PIN have been regarded by some authors (45,61,62) as "atypical cribriform lesion" or "atypical cribriform intraductal
lesion insufficient for the diagnosis of IDC-P," and their identification in isolation in biopsy should warrant a repeat biopsy.
Rescue therapies include the enlargement of sphincterotomy, EPLBD, extracorporeal, intraductal
(laser or electrohydraulic), or mechanical lithotripsy.
Differential diagnosis should always include all the pancreatic cystic lesions: mucinous cystic neoplasm, intraductal
papillary mucinous neoplasm (IPMN), neuroendocrine tumors, pancreatic ductal adenocarcinoma, pseudocyst, due to the most frequently gross appearance of a mixed cystic-solid lesions.
The lesions evaluated in this study that can become cancerous are known as intraductal
papillary mucinous neoplasms.
We will continue to advance our intraductal
microcatheter technology program: continuing the Phase 2 clinical study using our proprietary intraductal
microcatheter technology to administer fulvestrant in the Window of Opportunity for women with ER+ breast cancer, and continuing our R&D program to develop TRAP to administer immunotherapies for women with triple negative breast cancer and/or BRCA+ breast cancer.
Molecular and immunohistochemical analysis of intraductal
papillary neoplasms of the biliary tract.